Figure 4.

Pathways controlled by AKAP12 in cancer. AKAP12 suppresses cancer progression by disengaging adhesion- and growth factor–induced activation of Src-FAK complexes from transducing Raf/MEK/ERK- and JNK-mediated proliferation, angiogenesis, and cytoskeletal remodeling signals, possibly through a direct binding of AKAP12 to the Src-SH3 domain, resulting in the altering of Src-FAK signaling complexes. AKAP12 also directly inhibits PKC activation by a direct scaffolding function. In contrast, AKAP12 scaffolding of PKA facilitates cAMP-induced cytoskeletal remodeling.